Assist Prof Dr. Lili Xu, at China Pharmaceutical University,China
Author Profile
🎓 Academic and Professional Background:
Lili Xu, Ph.D., earned her degree in Pharmaceutical Chemistry and Biology from China Pharmaceutical University in 2017. She conducted postdoctoral research at the same institution until July 2021 when she was promoted to Associate Researcher. She leads two projects funded by the National Natural Science Foundation of China and two by the Natural Science Foundation of Jiangsu Province. With over 40 SCI papers and six patents, she’s received awards like the Shimadzu Young Scholar, Gold Prize of the Macedonia Invention, and Silver Prize of the Geneva Invention Award.
🔬 Research and Innovations:
Completed/Ongoing Research Projects:
- National Natural Science Foundation of China, General Program: Screening, design, and synthesis of novel inhibitors that interfere with the formation of NEK7-NLRP3 inflammasome complexes and their application in the treatment of acute and chronic inflammation-related diseases (82173675), 2022.01~2025.12, RMB 550,000, principal investigator, ongoing.
- National Natural Science Foundation of China, Youth Program: Discovery, design, synthesis, and exploration of NLRP3 inflammasome-targeted inhibitors for the treatment of non-controllable inflammatory disorders (81803354). 2019.01~2021.12, RMB 210,000, principal investigator, completed.
- Natural Science Foundation of Jiangsu Province, Youth Program: Design and synthesis of NLRP3-targeted inhibitors based on skeleton reconstruction strategy, and exploration of their therapeutic effects on non-controllable inflammatory disorders (BK20180564). 2018.07~2021.06, RMB 200,000, principal investigator, completed.
- Natural Science Foundation of Jiangsu Province, General Program: Discovery, design, synthesis, and activity evaluation of novel inhibitors targeting TLR4-MD2 immune-inflammatory pathway for drug addiction treatment (BK20231480). 2023-07-01~2026-06-30, RMB 100,000, principal investigator, ongoing.
- China Postdoctoral Science Foundation, General Program: Discovery, optimization, activity evaluation, and mechanistic studies of ULK1 inhibitors (2017M620232), 2018.01~2021.01, RMB 80,000, principal investigator, completed.
- Fundamental Research Funds for the Central Universities, Key Program: Discovery and validation of novel oxadiazole-based anti-inflammatory target proteins using proteomics and molecular probe technology, 2021.01~2022.12, RMB 150,000, principal investigator, ongoing.
- National Natural Science Foundation of China, General Program: Discovery of ubiquitin E3 ligase Cbl-b inhibitors based on substrate-binding crucial features and exploration of their application in tumor immunotherapy (82173680), 2022.01~2025.12, RMB 550,000, ongoing, participating.
- National Natural Science Foundation of China, General Program: Discovery of targeted inducers of tau protein degradation conjugates based on ubiquitin E3 ligase Keap1 and exploration of their therapeutic application in Alzheimer’s disease (81773581), 2018.01~2021.12, RMB 620,000, completed, participating.
- National Natural Science Foundation of China, Youth Program: Research on the application of GNN-based Raman hotspot regulation method in drug-target interaction (81803485), 2019.01~2021.12, RMB 210,000, completed, participating.
🏭 Consultancy/Industry Projects:
- Institutional commissioned project: Detection of drugs in urban wastewater in Jiangyin City, commissioned by the Jiangyin Public Security Bureau, RMB 69,100, principal investigator, ongoing.
- Industry commissioned project: Joint laboratory for drug detection between China Pharmaceutical University and Jiangsu Kangda Detection Technology Co., Ltd. (co-build laboratory), RMB 200,000, principal investigator, ongoing.
📚 Books Published (ISBN):
Currently, no books have been published.
💡 Patents Published/Under Process:
As the first inventor, Lili Xu has obtained 5 granted invention patents; as the fourth inventor, she has obtained 1 granted invention patent. Patent numbers: ZL201911146468.0, ZL202110442073.6, ZL202010483840.3, ZL201910366733.X, ZL202210071005.8, ZL202210146811.7.
.
🎓Publication Top Noted: